Christina Mattina is a journalist for the American Journal of Managed Care (AJMC). She covers a wide range of topics related to healthcare, including healthcare affordability, chronic disease management, healthcare policy, and healthcare research. Her articles provide insights into the challenges and advancements in the managed care industry.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Christina Mattina's articles primarily focus on healthcare, medical research, and managed care. She frequently cites data and includes expert commentary in her coverage. Therefore, when reaching out to her, consider offering access to new data or providing experts who can provide insightful commentary on the latest trends in healthcare and medical research.
Given her strong emphasis on citing data, she may be particularly interested in receiving pitches that present compelling statistics or findings from reputable sources within the healthcare industry. Additionally, given the broad range of topics she covers within healthcare and pharmaceuticals, pitching stories related to unmet needs among patients with severe asthma or COPD could be well received by Christina Mattina.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Christina Mattina
Change takes effect in 2025 and could benefit more than one million Medicare beneficiaries
By: Christina Mattina
The FDA added another indication for semaglutide (Wegovy), expanding its use to reduce the risk of cardiovascular death, heart attack, or stroke in adults who have cardiovascular disease (CVD) and overweight or obesity.
By: Christina Mattina
Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.
During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
By: Christina Mattina
After years of efforts to reduce low-value care, panelists at the 2024 Value-Based Insurance Design Summit proposed a new strategy: drawing a line in the sand that payers will not be on the hook for these services.
By: Christina Mattina
A review explores the evidence supporting the use of circulating tumor DNA (ctDNA) liquid biopsies to help direct the evaluation and management of EGFR-mutated non–small cell lung cancer (NSCLC), including for assessing resistance to certain treatment options.
By: Christina Mattina
Results presented at the National Community Oncology Dispensing Association International Spring Forum describe meaningful improvements in functioning among patients who received the oral gamma secretase inhibitor to treat progressing desmoid tumors.
By: Christina Mattina
As CMS’ suite of value-based and accountable care models evolves, leaders from across the agency detailed how they are working together to streamline quality reporting and encourage the move to a population health mindset while addressing providers’ concerns.
By: Christina Mattina
By prioritizing well-being, both the public and private sectors can come together in partnerships to address social needs and social determinants of health.
By: Christina Mattina
A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
(833) 317-6278 